Impact of Hormonal Therapy on GSTP1 Detection in Prostate Cancer
Author Information
Author(s): Jens Kollermann, Carsten Kempkensteffen, Burkhard Helpap, Mark Schrader, Hans Krause, Markus Muller, Kurt Miller, Martin Schostak
Primary Institution: Charité – Universitätsmedizin Berlin
Hypothesis
Does hormonal therapy affect the detection of GSTP1 hypermethylation in prostate cancer patients?
Conclusion
Hormonal therapy generally does not alter GSTP1 hypermethylation detection, but some patients may show a change from positive to negative status.
Supporting Evidence
- 13 out of 15 patients showed GSTP1 hypermethylation after hormonal therapy.
- All initial tumor samples from 8 patients showed GSTP1 hypermethylation.
- Two patients showed a negative GSTP1 status after hormonal therapy despite being positive before.
Takeaway
This study looked at how hormonal treatment affects a specific gene marker in prostate cancer. Most patients still showed the marker after treatment, but a few did not.
Methodology
Paraffin embedded tumor samples from radical prostatectomy specimens were assessed by methylation-specific PCR.
Limitations
The study had a small sample size and lacked untreated tumor samples for some patients.
Participant Demographics
Mean age was 65 years, with a range from 57 to 73 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website